In vitro diagnostic industry is with the development of modern laboratory medicine, and in turn led to the rapid development of laboratory medicine, basic medicine and other disciplines. At present, 2/3 of the global medical decision-making is based on diagnostic information, and diagnostic expenditures accounted for only 1% of the total medical expenditures, diagnostic technology to further improve the prevention, diagnosis and treatment of diseases has a positive significance, diagnostic reagent industry also has a broad space for development. What are the relevant in vitro diagnostic concept stocks?
In Vitro Diagnostics Concept Stocks List
Libon Instruments: In Vitro Diagnostics Leader. The company is mainly engaged in medical electronic equipment products and in vitro diagnostic products research and development, production, sales and service.
HUA Genetics: in vitro diagnostics leader. The company's wholly-owned subsidiary European Medicine's fetal chromosome aneuploidy detection kit products, recently obtained the CE certification issued by the British Standards Institution for in vitro diagnostic medical devices.
Other in vitro diagnostic concept stocks are:
Berry Genetics: NextSeqCN500 high-throughput gene sequencer can be used in the clinic with the national drug supervision and management department approved in vitro diagnostic reagents as well as the instrument supporting the randomized software with the test, and is not used in the sequencing of the whole human genome or from the beginning of the sequencing, "to become the Clinical general-purpose NGS sequencing platform.
Kehua Bio: a leading in vitro diagnostic company, the old IDV diagnostic leader. The former life is Shanghai Kewa biochemical reagent laboratory, biochemical and enzyme immunity is the core business from the beginning, but also is the early start of chemiluminescence product research and development enterprises, molecular diagnostic business is also gradually become the performance of the growth momentum. Under the epidemic, the company's diagnostic business also stood on the wind, to obtain the EU market free sales certificate.
*ST Toyo: the acquisition of the United States Avioq, its main products for HV test reagents, HTLV test reagents and related mass spectrometry test, September 18, obtained four in vitro diagnostic reagents medical device registration certificate; 17 years reagents and instruments revenue of 64,834,600 yuan, accounting for 14.19%.
Guangyu Group: the company holds a 10% stake in Hangzhou Guangke Ander Biological Science and Technology Co., Ltd, the subject of the main in vitro diagnostic reagents, mainly for the early diagnosis of cancer.